BAM
IBRX icon

Belpointe Asset Management’s ImmunityBio IBRX Stock Holding History

Belpointe Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,000
Closed -$3.64K – 1836
2023
Q1 		$3.64K Hold
2,000
– – ﹤0.01% 3126
2022
Q4 		$10.1K Buy
+2,000
New +$11K ﹤0.01% 2611

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return

Belpointe Asset Management's IBRX Position: Q2 2023 in Review

Belpointe Asset Management sold out of ImmunityBio (IBRX) in Q2 2023, closing a stake of 2,000 shares — an estimated $3.64K sold.

Belpointe Asset Management first reported a position in IBRX in Q4 2022 and held it in 2 quarters. The position peaked at $10.1K in Q4 2022. 117 funds tracked by Wall St. Rank hold IBRX as of Q2 2023.

  • Belpointe Asset Management reported no remaining ImmunityBio position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 2,000 ImmunityBio shares in Q2 2023, an estimated $3.64K.
  • Belpointe Asset Management first reported a position in ImmunityBio in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's ImmunityBio position peaked at $10.1K in Q4 2022.
  • 117 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.